1	Effects of dietary interventions focused on adding base in the management of					
2	metabolic acidosis in adults with chronic kidney disease: A protocol for					
3	systematic review and meta-analysis of randomized clinical trials					
4						
5	Sepideh Mahboobi <sup>1</sup> , Rebecca Mollard <sup>1</sup> , <sup>2</sup> , Navdeep Tangri <sup>2</sup> , <sup>3</sup> , Nicole Askin <sup>4</sup> , Rasheda Rabbani <sup>5</sup> , Ahmed					
6	M. Abou-Setta <sup>6</sup> , Dylan Mackay <sup>1,7</sup>					
7						
8	1. Department of Human Nutritional Sciences, Faculty of Agriculture and Food Sciences,					
9	University of Manitoba, Winnipeg, MB, Canada					
10	2. Chronic Disease Innovation Center, Seven Oaks Hospital, Winnipeg, Manitoba, Canada					
11	3. Department of Internal Medicine, Max Rady Faculty of Medicine, Rady Faculty of Health					
12	Sciences, University of Manitoba, Winnipeg, Manitoba, Canada					
13	4. Neil John Maclean Health Sciences Library, University of Manitoba, Winnipeg, Manitoba, Canada					
14	5. George and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady					
15	Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada					
16	6. Department of Community Health Sciences, Max Rady Faculty of Medicine, Rady Faculty of					
17	Health Sciences, University of Manitoba, Winnipeg, Canada					
18	7. Department of Internal Medicine, Section of Endocrinology, Max Rady Faculty of Medicine,					
19	Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada					
20						
21						
22	Name and full address of corresponding author:					
23	Dylan MacKay, Department of Food and Human Nutritional Sciences, Faculty of Agriculture and Food					
24	Sciences, and Department of Internal Medicine, Section of Endocrinology, Rady Faculty of Health					
25	Sciences, 196 Innovation drive, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.					
26	Email: dylan.mackay@umanitoba.ca					
27						
28						

### 29 Abstract

30 **Background:** Metabolic acidosis is a common complication of chronic kidney disease (CKD) which can impair the function of multiple organs and accelerate CKD progression to kidney failure. The condition is 31 32 usually treated with sodium bicarbonate (NaHCO3), which is an alkali salt. Although effective, alkali therapy has numerous side effects including gastric discomfort and bloating, with many people having 33 34 difficulty tolerating higher doses. Research has shown that base producing fruit and vegetables may have 35 the ability to increase serum bicarbonate concentrations similar to what is achieved with alkali therapy, 36 but also provides added benefits. This systematic review aims to identify, critically-appraise and meta-37 analyze findings from randomized clinical trials (RCTs) comparing the effects of dietary interventions, 38 including base producing fruit and vegetables, on serum bicarbonate concentrations as well as other 39 factors related to kidney function in adult patients with CKD. 40 **Methods:** RCTs (in adult participants (18 years of age or older), with CKD will be included in the study. 41 Studies will be excluded if participants are undergoing dialysis or have chronic obstructive pulmonary 42 disease (COPD) requiring oxygen therapy. The interventions of interest are any dietary intervention aimed at manipulating dietary acid load, compared with usual care, no treatment or placebo. Our primary 43 44 outcome measure will be changes in serum bicarbonate concentration, while other parameters related to 45 kidney function will be considered as secondary outcomes. A knowledge synthesis librarian developed a 46 literature search strategy for MEDLINE (Ovid). The search strategy was then adjusted for use in 47 Cochrane Central (Ovid), Embase (Ovid), Web of Science Core Collection (Clarivate) and CINAHL 48 (EBSCO). Two independent reviewers will select studies for eligibility in Covidence and data extraction 49 will be conducted using a custom MS Excel worksheet. We are planning to perform meta-analysis 50 wherever possible using random effects model. Standardized mean difference (95% confidence interval)

and risk ratio will be used to present continuous and dichotomous data, respectively. The assessment of

52 publication bias will be performed using funnel plots and Egger's regression test while  $I^2$  statistics will be

- used to assess heterogeneity. We are planning to perform subgroup analysis to deal with potential
- 54 heterogeneity.
- 55 **Discussion:** The results of this systematic review and meta-analysis will be useful in designing effective
- 56 dietary strategies for the management of CKD-related metabolic acidosis.
- 57 Systematic review registration: The present systematic review is registered in International
- 58 Prospective Register of Systematic Reviews (PROSPERO) (<u>https://www.crd.york.ac.uk/</u>, registration ID:
- **59** CRD42022342612).

## 60 Key words:

61 Dietary acid load, Metabolic acidosis, Chronic kidney disease, Fruit and vegetables

62

#### Background 64

65	Chronic Kidney Disease (CKD) is a progressive condition and is recognized as a leading health					
66	concern worldwide (1, 2). The condition is categorized into 5 stages based on Glomerular					
67	Filtration Rate (GFR); Early stages are asymptomatic, but can progress rapidly to kidney failure					
68	within months in some individuals (3). CKD is associated with increased risk of cardiovascular					
69	disease (CVD), kidney failure requiring renal replacement therapy, poor quality of life, and					
70	mortality (4). The global prevalence of CKD has been estimated 13.4% (5). According to a					
71	cross-sectional study, the overall estimated prevalence of stage 3 to 5 CKD in the Canadian					
72	population was 71.9 per 1000 individuals, from 2010 to 2015 (6).					
73	Kidneys play a crucial role in maintaining acid-base balance by reabsorbing bicarbonate from					
74	filtrate and excreting acid and ammonia into urine (7). The cause of metabolic acidosis in CKD					
75	is the inability of kidneys to excrete enough acid, leading to a positive H <sup>+</sup> balance and low CO2					
76	concentrations (13). As kidney function declines metabolic acidosis becomes a common					
77	complication in people with CKD and its prevalence increases with the decline in GFR,					
78	especially when GFR levels fall below 40 ml/min/1.73m <sup>2</sup> (8, 9). Although metabolic acidosis is					
79	usually mild to moderate in CKD, the condition can impair different organ systems, and					
80	contribute to increased morbidity and mortality (10, 11). Augmentation of inflammation, bone					
81	disease exacerbation, muscle wasting, and acceleration of CKD progression are among adverse					
82	effects related to metabolic acidosis (12).					
83	Sodium bicarbonate (NaHCO3) is an alkali salt commonly used in the treatment of metabolic					
84	acidosis (14), which may improve endothelial function and muscle mass and delay kidney failure					
85	(15). However, oral alkali therapy has been related to a number of side effects including gastric					
86	discomfort and bloating, with many people having difficulty tolerating higher doses (16).					

87	Furthermore, concerns have been raised about sodium retention, volume overload and
88	exacerbating pre-existing hypertension when sodium bicarbonate is used (17).
89	Daily acid load is mostly determined by the metabolism of dietary constituents into base or acid
90	production. Sulfur containing amino acids (abundant in animal sources of protein) lead to H <sup>+</sup>
91	production while fruit and vegetables are base producing (9). Dietary H <sup>+</sup> reduction is hence
92	another strategy in the management of CKD-related metabolic acidosis, by reducing the intake of
93	acid producing components (such as animal proteins) as opposed to adding base by increasing
94	fruit and vegetables consumption (18).
95	Recent studies have reported that treating metabolic acidosis with fruit and vegetables might be
96	as effective as alkali therapy in improving disease state by modifying HCO3 concentrations,
97	while also reducing blood pressure and preserving eGFR with no concerns regarding adverse
98	events (19, 20). One clinical trial has even shown that fruit and vegetables treatment not only
99	improved metabolic acidosis, but also reduced CVD risk better than NaHCO3 (21). There is a
100	need to integrate existing findings on the effects of adding base through fruit and vegetables
101	consumption in the management of CKD-related metabolic acidosis. This proposed systematic
102	review will evaluate the efficacy and safety of using fruit and vegetables to manage metabolic
103	acidosis, as well as look at patients' compliance and tolerability, looking to identify limitations in
104	the current literature and set directions for future research.(23)

### 105 Methods

106 Aim

107 This systematic review aims to summarize findings from RCTs comparing dietary interventions108 focused on adding base (via fruit and vegetables consumption) with dietary interventions

- focusing on lowering acid load versus placebo/usual care/no treatment in the management ofmetabolic acidosis in outpatient adults with CKD.
- 111 This study protocol was developed using Cochrane systematic review methodology (24) and is
- 112 reported according to Preferred Reporting Items for Systematic review and Meta-Analysis
- 113 Protocols (PRISMA-P) guidelines (25). The protocol has been registered in International
- 114 Prospective Register of Systematic Reviews (PROSPERO) (<u>https://www.crd.york.ac.uk/</u>,
- 115 registration ID: CRD42022342612).
- 116

### 117 Study types and eligibility criteria

118 The following study types will be eligible for inclusion: Randomized controlled trials, and cross-

over randomized trials on adult participants (18 years of age or older), with CKD (as diagnosed

using any recognized diagnostic criteria or author-defined) with eGFR between 15 and 40

ml/min/1.73 m<sup>2</sup> and serum bicarbonate levels of 14-24 mEq/L. Studies will be excluded if

122 participants are undergoing dialysis or have chronic obstructive pulmonary disease (COPD)

123 requiring oxygen therapy.

124

### 125 Intervention and control groups

Any dietary guidance or modification looking to manipulate dietary acid load will be consideredas an intervention. The comparators will be usual care/ no treatment or placebo.

#### 129 *Outcome measures*

Our primary outcome will be change in serum bicarbonate concentrations (mEq/L). Secondary 130 131 outcomes are systolic and diastolic blood pressure, heart rate, anthropometric measurements, blood urea nitrogen (BUN), creatinine, eGFR, glucose, albumin, calcium, chloride, phosphorous, 132 potassium, sodium and HbA1c, albumin/creatinine ratio in urine samples, quality of life, reported 133 134 adverse effects, mortality and KDIGO (Kidney Disease Improving Global Outcomes) criteria for acute kidney injury. This systematic review will also investigate the safety and tolerability of 135 136 dietary interventions (either increasing fruit and vegetables intake or decreasing animal proteins), 137 as well as bicarbonate therapy or placebo, in the management of metabolic acidosis in people with CKD. 138 139 Study identification and selection 140

141 A knowledge synthesis librarian (NA) developed the literature search strategy for MEDLINE (Ovid) using a modified version of the SIGN RCT filter (26). This strategy was then peer-142 reviewed by a second independent librarian using the PRESS checklist (23). The final search 143 144 strategy was then adjusted for use in Cochrane Central (Ovid), Embase (Ovid), Web of Science Core Collection (Clarivate) and CINAHL (EBSCO). The search strategy for this systematic 145 146 review is presented in **Supplementary file 1.** Records retrieved by the search will be uploaded in Covidence systematic review management software and screened for eligibility by two 147 independent reviewers (SM and RM). Ineligible citations will be recorded and the number and 148 149 reason for exclusion will be documented at the full-text article screening stage. Disagreements on the eligibility of citations will be discussed by two reviewers with a third reviewer (DM) to 150 adjudicate, as required. Included citations will be limited to the English language. 151

### 152 Data extraction and management

153	Data extraction will be done using forms developed, stored and managed in MS Excel					
154	worksheet. Two reviewers will independently extract the data from all included studies. Any					
155	concerns or disagreements will be discussed and settled between the two reviewers and a third					
156	reviewer will adjudicate the issues that cannot be resolved by the two reviewers.					
157	The following data will be extracted from the included studies:					
158	• Study details: name of first author, year of publication, study period, country, study size,					
159	and funding source					
160	• Study population details: type of population (age, sex distribution, comorbidities, and					
161	socioeconomic status)					
162	• Intervention details: name, type, method of intervention, measure					
163	(amount/extent/dosage), foods provided or recommended, foods instructed to avoid,					
164	duration					
165	• Outcome details: Data will be extracted at the end of the trial and at the longest reported					
166	follow-up.					
167	Risk-of-bias assessment					
168	The risk of bias will be assessed through the Cochrane Risk of Bias Tool 2.0. (27). The tool will					

provide an assessment score in the forms of high, some concerns, and low risk of bias in each of the following areas: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome, and bias in selection of the reported result. Any disagreements or issues will be discussed by the two reviewers or by involving a third reviewer if required.

### 175 Data Analysis

176	We are planning to	conduct meta-ana	lysis wherever	possible, using	a random effects model.

- 177 Continuous data will be presented as mean differences or standardized mean differences where
- measures of the same outcome are with different scales, with 95% confidence intervals.
- 179 Dichotomous data will be assessed and reported as a risk ratio with 95% confidence intervals.
- 180 Statistical heterogeneity will be assessed between the included studies by using the I-squared  $(I^2)$
- 181 statistic (28). Our assessment of publication bias will be completed through the use of funnel
- plots (29) and using Egger's regression test (30) if there are at least 10 included trials in the
- 183 meta-analysis.
- 184 We are planning to perform a prespecified subgroup analyses investigating dietary intervention
- 185 method (adding base vs. reducing acid) and type of intervention (providing food vs. dietary
- 186 guidance only). We will also conduct sensitivity analyses looking at diabetes comorbidity
- 187 (people with diabetes vs. those without diabetes using regression against proportion of people
- 188 with diabetes in trial cohort), trial type (parallel vs. crossover) sex, CKD stage, and geographical

189 region.

### 191 Discussion

192 Metabolic acidosis is of the most common consequences of CKD, with a leading role in CKD-193 related morbidity and mortality (31). Data from both observational and interventional studies has shown that correction of metabolic acidosis by NaHCO3 or diets rich in base producing fruit and 194 195 vegetables may have the ability to slow the rate of decline in kidney function (32). Patients on Na<sup>+</sup>-based alkali therapy are at an increased risk of worsened hypertension or volume control, 196 197 especially at lower eGFR (33). On the other hand, the usual dietary habits of developed countries 198 often result in diets with increased production of acid equivalents (34). Therefore, dietary interventions targeting the addition of base producing fruit and vegetables may be more 199 200 appropriate than alkaline therapy in the management of CKD induced metabolic acidosis. Some 201 small single center trials have been conducted on the effects of fruit and vegetables consumption on different outcomes related to kidney function, in different stages of CKD. Some review 202 203 articles have included effects of dietary interventions in the management of CKD (34, 35) which 204 have provided general information in the topic. To the best of our knowledge, our study will be 205 the first to systematically review data from randomized studies aiming at evaluating the effects of adding dietary base equivalents via fruit and vegetables consumption in the management of 206 207 CKD-related metabolic acidosis. Our study is not obstacle-free. The number of studies meeting 208 our criteria might be few and heterogeneity might arise due to different settings and clinical 209 stages. Nevertheless, we have prepared a plan for prespecified subgroup analysis based on dietary interventions (adding base vs. reducing acid), type of intervention (providing food vs. 210 recommendation only), sex, diabetes comorbidity, CKD stages and region. The findings of this 211 212 study will be useful to guide clinical practice regarding the use of base producing fruit and

213	vegetables as a	n alternative o	ption to oral	alkali therapy	. Furthermore.	, this study	y will find
-----	-----------------	-----------------	---------------	----------------	----------------	--------------	-------------

214 limitations of the current literature and inform the design of future research in this area

#### 215 Abbreviations

- 216 BUN: Blood Urea Nitrogen; CKD: Chronic Kidney Disease; COPD: Chronic Obstructive
- 217 Pulmonary Disease; CVD: Cardiovascular Disease; GFR: Glomerular Filtration Rate; KDIGO:
- 218 Kidney Disease Improving Global Outcomes; PRISMA-P: Preferred Reporting Items for
- 219 Systematic review and Meta-Analysis Protocols; PROSPERO: Prospective Register of
- 220 Systematic Reviews; RCT: Randomized Clinical Trial

### 221 Supplementary information

- 222 Supplementary file 1: search strategy
- 223 Supplementary file 2: PRISMA-P 2015 checklist

#### 224 Acknowledgement

225 We would like to thank Tyler Ostapyk for conducting the PRESS review of our search strategy.

226

#### 227 Authors contribution

228 SM drafted the review protocol manuscript. NA is a health sciences librarian who developed the

search strategy based on input from DM, RM, AMAS, RR NT and SM. AAB and RB provided

- content expertise in knowledge synthesis and meta-analysis. NT provided content expertise in
- chronic kidney disease. RM and DM are content experts in nutritional interventions. Each author
- 232 reviewed and made substantial contributions to this manuscript. All authors have read and
- approved the final manuscript.

# 234 Funding

- 235 This study is funded by University of Manitoba and Seven Oaks Chronic Disease Innovation
- 236 Centre.

# 237 Availability of data and material

- 238 The Endnote database, as well as final extraction sheets and data regarding risk of bias
- assessment will be available upon request.

# 240 **Competing interest**

241 None

# 242 Ethics approval and consent to participate

243 Not applicable

## 244 **Consent for publication**

245 Not applicable

# 247 **References**

248

Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. The Lancet.
 2021;398(10302):786-802.
 Lv J-C, Zhang L-X. Prevalence and Disease Burden of Chronic Kidney Disease. In: Liu B-C, Lan H-Y,

Lv L-L, editors. Renal Fibrosis: Mechanisms and Therapies. Singapore: Springer Singapore; 2019. p. 3-15.
 Lv L-L, editors. Renal Fibrosis: Mechanisms and Therapies. Singapore: Springer Singapore; 2019. p. 3-15.

253 3. Levey AS, Coresh J. Chronic kidney disease. The Lancet. 2012;379(9811):165-80.

2544.Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications255of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney international256supplements. 2017;7(2):122-9.

Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global Prevalence of
 Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLOS ONE. 2016;11(7):e0158765.

Bello AK, Ronksley PE, Tangri N, Kurzawa J, Osman MA, Singer A, et al. Prevalence and
 Demographics of CKD in Canadian Primary Care Practices: A Cross-sectional Study. Kidney

261 International Reports. 2019;4(4):561-70.

7. Nagami GT, Hamm LL. Regulation of Acid-Base Balance in Chronic Kidney Disease. Advances in
 chronic kidney disease. 2017;24(5):274-9.

2648.Stancu S, Mircescu G, Mocanu A, Capusa C, Stefan G. Metabolic Acidosis of Chronic Kidney265Disease and Cardiovascular Disorders. Maedica. 2018;13(4):267-72.

2669.Raphael KL. Metabolic Acidosis in CKD: Core Curriculum 2019. American journal of kidney267diseases : the official journal of the National Kidney Foundation. 2019;74(2):263-75.

10. Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2005;45(6):978-93.

11. Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with
 chronic kidney disease. Kidney International. 2005;67:S21-S7.

27312.Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney274disease. Pediatric Nephrology. 2011;26(1):19-28.

13. Raphael KL. Metabolic Acidosis in CKD: Core Curriculum 2019. American Journal of Kidney
Diseases. 2019;74(2):263-75.

14. Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal
aluminum absorption. Kidney International. 1990;38(5):937-41.

279 15. Chen W, Abramowitz MK. Advances in management of chronic metabolic acidosis in chronic
280 kidney disease. Current opinion in nephrology and hypertension. 2019;28(5):409-16.

28116.Sy J, Chen JLT, Kalantar-Zadeh K. New solutions to old problems-metabolic acidosis in chronic282kidney disease. Annals of translational medicine. 2020;8(19):1256.

283 17. Chen W, Abramowitz MK. Treatment of metabolic acidosis in patients with CKD. American

journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;63(2):311-7.

18. Goraya N, Wesson DE. Management of the Metabolic Acidosis of Chronic Kidney Disease.
Advances in chronic kidney disease. 2017;24(5):298-304.

19. Goraya N, Simoni J, Jo C-H, Wesson DE. A Comparison of Treating Metabolic Acidosis in CKD
Stage 4 Hypertensive Kidney Disease with Fruits and Vegetables or Sodium Bicarbonate. Clinical Journal
of the American Society of Nephrology. 2013;8(3):371.

290 20. Goraya N, Simoni J, Jo C-H, Wesson DE. Treatment of metabolic acidosis in patients with stage 3

chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and

292 preserves glomerular filtration rate. Kidney International. 2014;86(5):1031-8.

Goraya N, Munoz-Maldonado Y, Simoni J, Wesson DE. Fruit and Vegetable Treatment of Chronic

294 Kidney Disease-Related Metabolic Acidosis Reduces Cardiovascular Risk Better than Sodium 295 Bicarbonate. American journal of nephrology. 2019;49(6):438-48. 296 22. Goraya N, Munoz-Maldonado Y, Simoni J, Wesson DE. Treatment of Chronic Kidney Disease-297 Related Metabolic Acidosis With Fruits and Vegetables Compared to NaHCO<sub>3</sub> Yields More 298 and Better Overall Health Outcomes and at Comparable Five-Year Cost. Journal of Renal Nutrition. 299 2021;31(3):239-47. 300 McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of 23. 301 Electronic Search Strategies: 2015 Guideline Statement. Journal of Clinical Epidemiology. 2016;75:40-6. 302 Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for 24. 303 systematic reviews of interventions: John Wiley & Sons; 2019. 304 25. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting 305 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic 306 reviews. 2015;4(1):1-9. 307 Scotland HI. Scottish Intercollegiate Guidelines Network (2021). Search filters [updated 22] 26. 308 August 2022. Available from: https://www.sign.ac.uk/what-we-do/methodology/search-filters/. 309 27. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for 310 assessing risk of bias in randomised trials. bmj. 2019;366. 311 Pathak M, Dwivedi SN, Deo S, Sreenivas V, Thakur B. Which is the preferred measure of 28. 312 heterogeneity in meta-analysis and why? A revisit. Biostat Biometrics Open Acc. 2017;1:1-7. 313 Light RJ, Richard J, Light R, Pillemer DB. Summing up: The science of reviewing research: Harvard 29. 314 University Press; 1984. 315 30. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical 316 test. Bmj. 1997;315(7109):629-34. 317 Kuczera P, Ciaston-Mogilska D, Oslizlo B, Hycki A, Wiecek A, Adamczak M. The Prevalence of 31. 318 Metabolic Acidosis in Patients with Different Stages of Chronic Kidney Disease: Single-Centre Study. 319 Kidney and Blood Pressure Research. 2020;45(6):863-73. 320 32. Goraya N, Wesson DE. Clinical evidence that treatment of metabolic acidosis slows the 321 progression of chronic kidney disease. Current opinion in nephrology and hypertension. 2019;28(3):267-322 77. 323 33. Remer T. Influence of nutrition on acid-base balance-metabolic aspects. European journal of 324 nutrition. 2001;40(5):214-20. 325 34. Siener R. Dietary Treatment of Metabolic Acidosis in Chronic Kidney Disease. Nutrients. 326 2018;10(4).

327 35. Rodrigues Neto Angéloco L, Arces de Souza GC, Almeida Romão E, Garcia Chiarello P. Alkaline

- 328 Diet and Metabolic Acidosis: Practical Approaches to the Nutritional Management of Chronic Kidney
- 329 Disease. Journal of Renal Nutrition. 2018;28(3):215-20.

330

293

21.